Pulmonary Manifestations of Collagen Diseases

Carrera, Luis Gómez; Hernán, Gema Bonilla

doi:10.1016/j.arbr.2012.11.017

Cited by 15 publications

(9 citation statements)

References 116 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Interestingly, pulmonary endothelium dysfunction has also been described as a key stage for the development of lung damage and the subsequent onset and progression of interstitial lung disease (ILD). ILD represents one of the main causes of mortality in patients with RA, being the early detection of pulmonary involvement crucial to avoid an irreversible lung damage in these patients ( Gómez-Carrera and Bonilla-Hernan, 2013 ; Bacha et al, 2017 ; Hyldgaard et al, 2017 ; Zamora-legoff et al, 2017 ; Bendstrup et al, 2019 ; Manfredi et al, 2021 ). However, the early diagnosis of RA-ILD + constitutes a challenge for the clinicians because of the absence of symptoms in early or mild disease in some patients as well as the similarity of clinical, pathological, and epidemiological features with idiopathic pulmonary fibrosis (IPF), the most severe ILD ( Paulin et al, 2015 ; Bendstrup et al, 2019 ; Atienza-Mateo et al, 2020 ; Manfredi et al, 2021 ).…”

Section: Introductionmentioning

confidence: 99%

Elevated VCAM-1, MCP-1 and ADMA serum levels related to pulmonary fibrosis of interstitial lung disease associated with rheumatoid arthritis

Pulito‐Cueto

Remuzgo‐Martínez

Genre

et al. 2022

Front. Mol. Biosci.

View full text Add to dashboard Cite

Introduction: Early diagnosis of interstitial lung disease (ILD) associated with rheumatoid arthritis (RA) constitutes a challenge for the clinicians. Pulmonary vasculopathy is relevant in the development of interstitial lung disease. Accordingly, we aimed to explore the role of vascular cell adhesion molecule-1 (VCAM-1), monocyte chemoattractant protein-1 (MCP-1) and asymmetric dimethylarginine (ADMA), key molecules in the vasculopathy, as potential biomarkers of pulmonary fibrosis in RA-ILD+.Methods: We included 21 RA-ILD+ patients and two comparative groups: 25 RA-ILD- patients and 21 idiopathic pulmonary fibrosis (IPF) patients. Serum levels of the molecules were determined by ELISA, and mRNA expression was quantified by qPCR.Results: VCAM-1, MCP-1 and ADMA serum levels were increased in RA-ILD+ patients in relation to RA-ILD- and IPF patients. Additionally, RA-ILD+ patients exhibited increased CCL2 (gene encoding MCP-1) and decreased PRMT1 (gene related to ADMA synthesis) mRNA expression in relation to RA-ILD- patients. A lower expression of VCAM1, CCL2, and PRMT1 was observed in RA-ILD+ patients when compared with those with IPF. Furthermore, MCP-1 serum levels and PRMT1 mRNA expression were positively correlated with RA duration, and ADMA serum levels were positively associated with C-reactive protein in RA-ILD+ patients.Conclusion: Our study suggests that VCAM-1, MCP-1 and ADMA could be considered as useful biomarkers to identify ILD in RA patients, as well as to discriminate RA-ILD+ from IPF, contributing to the early diagnosis of RA-ILD+.

show abstract

Section: Introductionmentioning

confidence: 99%

Elevated VCAM-1, MCP-1 and ADMA serum levels related to pulmonary fibrosis of interstitial lung disease associated with rheumatoid arthritis

Pulito‐Cueto

Remuzgo‐Martínez

Genre

et al. 2022

Front. Mol. Biosci.

View full text Add to dashboard Cite

show abstract

“…Various types of collagen have been recognized as the vital players in a group of systemic inflammatory diseases of autoimmune origin, termed connective tissue diseases, that affect a wide range of organs and systems (Gómez Carrera and Bonilla Hernan, 2013). In this sense, an in-depth study of LAIR-1 function and biology may be of profound biomedical significance.…”

Section: Discussionmentioning

confidence: 98%

Comparison of LAIR-1 genetic pathways in murine vs human internal organs

Sun¹,

Jiao²,

Wei³

et al. 2014

Gene

View full text Add to dashboard Cite

“…Pulmonary involvement is frequently reported in paediatric RD, a heterogeneous group of systemic inflammatory diseases of autoimmune origin that include juvenile rheumatoid arthritis (RA), polymyositis, systemic lupus erythematosus, scleroderma, dermatomyositis, Sjogren's syndrome, Wegener's granulomatosis and systemic vasculitis …”

Section: Bronchiectasis and Coexisting Rd In Childrenmentioning

confidence: 99%

“…The association between bronchiectasis and RD is best described with juvenile RA. The prevalence of bronchiectasis in juvenile RA varies considerably in studies, with a prevalence up to 70% in adulthood and significantly fewer cases among the paediatric population, even though the absence of specific recommendations on the frequency of chest CT in these patients likely means that a number of asymptomatic patients remain undiagnosed . Of relevance is the observation that, in most cases, respiratory symptoms start during childhood or adolescence and frankly precede the first clinical appearance of arthritis .…”

Section: Bronchiectasis and Coexisting Rd In Childrenmentioning

confidence: 99%

“…A recent study of granulomatosis with polyangiitis (Wegener's) or microscopic polyangiitis not including children or adolescents found that bronchiectasis, documented in 38% of the cases, did not worsen patients’ outcome when anti‐myeloperoxidase anti‐neutrophil cytoplasm antibody‐associated vasculitis was expressed . Overall, when bronchiectasis is documented in association with RD, the outcome of the underlying disorder seems to be worse than without RD . In addition to this, the immune dysregulation due to immunosuppressive drugs likely results in more infectious complications, namely, recurrent pneumonia, and this significantly increases the risk of developing bronchiectasis.…”

Section: Bronchiectasis and Coexisting Rd In Childrenmentioning

confidence: 99%

See 1 more Smart Citation

Paediatric and adult bronchiectasis: Specific management with coexisting asthma, COPD, rheumatological disease and inflammatory bowel disease

2019

View full text Add to dashboard Cite

Bronchiectasis, conventionally defined as irreversible dilatation of the bronchial tree, is generally suspected on a clinical basis and confirmed by means of chest high-resolution computed tomography. Clinical manifestations, including chronic productive cough and endobronchial suppuration with persistent chest infection and inflammation, may deeply affect quality of life, both in children/adolescents and adults. Despite many cases being idiopathic or post-infectious, a number of specific aetiologies have been traditionally associated with bronchiectasis, such as cystic fibrosis (CF), primary ciliary dyskinesia or immunodeficiencies. Nevertheless, bronchiectasis may also develop in patients with bronchial asthma; chronic obstructive pulmonary disease; and, less commonly, rheumatological disorders and inflammatory bowel diseases. Available literature on the development of bronchiectasis in these conditions and on its management is limited, particularly in children. However, bronchiectasis may complicate the clinical course of the underlying condition at any age, and appropriate management requires an integration of multiple skills in a team of complementary experts to provide the most appropriate care to affected children and adolescents. The present review aims at summarizing the current knowledge and available evidence on the management of bronchiectasis in the other conditions mentioned and focuses on the new therapeutic strategies that are emerging as promising tools for improving patients' quality of life.

show abstract

Pulmonary Manifestations of Collagen Diseases

Cited by 15 publications

References 116 publications

Elevated VCAM-1, MCP-1 and ADMA serum levels related to pulmonary fibrosis of interstitial lung disease associated with rheumatoid arthritis

Elevated VCAM-1, MCP-1 and ADMA serum levels related to pulmonary fibrosis of interstitial lung disease associated with rheumatoid arthritis

Comparison of LAIR-1 genetic pathways in murine vs human internal organs

Paediatric and adult bronchiectasis: Specific management with coexisting asthma, COPD, rheumatological disease and inflammatory bowel disease

Contact Info

Product

Resources

About